title: Nitrophorin 2, a factor IX(a)-directed anticoagulant, inhibits arterial thrombosis without impairing haemostasis.
abstract: Nitrophorin 2 (NP2) is a 20 kDa lipocalin identified in the salivary gland of the blood sucking insect, Rhodnius prolixus. It functions as a potent inhibitor of the intrinsic pathway of coagulation upon binding to factor IX (FIX) or FIXa. Herein we have investigated the in vivo antithrombotic properties of NP2. Surface plasmon resonance assays demonstrated that NP2 binds to rat FIX and FIXa with high affinities (KD = 43 and 47 nM, respectively), and prolongs the aPTT without affecting the PT. In order to evaluate NP2 antithrombotic effects in vivo two distinct models of thrombosis in rats were carried out. In the rose Bengal/laser induced injury model of arterial thrombosis, NP2 increased the carotid artery occlusion time by ≍35 and ≍155%, at doses of 8 and 80 μg/kg, respectively. NP2 also inhibited thrombus formation in an arterio-venous shunt model, showing ≍60% reduction at 400 μg/kg (i.v. administration). The antithrombotic effect lasted for up to 48 hours after a single i.v. dose. Notably, effective doses of NP2 did not increase the blood loss as evaluated by tail-transection model. In conclusion, NP2 is a potent and long-lasting inhibitor of arterial thrombosis with minor effects on haemostasis. It might be regarded as a potential agent for the treatment of human cardiovascular diseases.
authors.affiliation: Instituto de Bioquímica Médica/CCS/UFRJ, Avenida Carlos Chagas Filho 373, Cidade Universitária, Ilha do Fundão, Rio de Janeiro 21941590, Brazil.
authors.forename: Daniella M
authors.initials: DM
authors.lastname: Mizurini
authors.forename: Ivo M B
authors.initials: IM
authors.lastname: Francischetti
authors.forename: John F
authors.initials: JF
authors.lastname: Andersen
authors.forename: Robson Q
authors.initials: RQ
authors.lastname: Monteiro
mesh_terms: D000818:Animals; D000925:Anticoagulants / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D004195:Disease Models, Animal; D015949:Factor IXa / Q000037:antagonists & inhibitors* / Q000378:metabolism; D005260:Female; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D006420:Hemeproteins / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D006487:Hemostasis / Q000187:drug effects*; D007275:Injections, Intravenous; D007700:Kinetics; D008297:Male; D010314:Partial Thromboplastin Time; D011485:Protein Binding; D011517:Prothrombin Time; D051381:Rats; D017208:Rats, Wistar; D012471:Salivary Proteins and Peptides / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D020349:Surface Plasmon Resonance; D013917:Thrombin / Q000378:metabolism; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D005343:Fibrinolytic Agents; D006420:Hemeproteins; D012471:Salivary Proteins and Peptides; C090560:nitrophorin; D015949:Factor IXa; D013917:Thrombin